JAKARTA – PT Itama Ranoraya Tbk (IRRA), health equipment manufacturer, scored operating revenue of IDR 1.08 trillion in Q3 2021, a massive upturn from the number reported in 2020 of IDR 141.05 billion. This surge resulted from the all-time high demand for COVID-19 test kits in the middle of this ongoing pandemic since early 2020.
Heru Firdaus Syarif, President Director of Itama Ranoraya, revealed that the highest revenue came from in vitro diagnostic products sales of IDR 1.04 trillion. Then, it was followed by sterile, non-electromedical equipment sales of IDR 29.64 billion and other products sales of IDR 9.47 billion. In comparison, in Q3 2020, in-vitro diagnostic products sales only generated IDR 33.17 billion, and sterile, non-electromedical equipment sales amounted to IDR 107.91 billion.
IRRA’s gross profit and operating profit were reported to reach IDR 188.06 billion and IDR 116.06 billion, respectively, proliferating from IDR 25.18 billion and IDR 11.35 billion recorded in the same period in 2020. Meanwhile, its profit before taxes and comprehensive profit were rounded up to IDR 109.21 billion a,d IDR 84.91 billion, way above the gain scored in Q3 2020 of IDR 11.37 billion and IDR 8.94 billion.
IRRA’s customers with contributions above 32% of total revenue were the Blood Transfusion Unit of DKI Jakarta Red Cross, PT Dharma Mitra Abadi, the Directorate of Public Medicine and Health Products of Ministry of Health, PT Semesta Medika Indonesia, and PT Sinergi Utama Sejahtera. (LK/ZH)